With virtual events likely to remain a firm fixture for some time, Owen Mumford Pharmaceutical Services has published a research report presenting the impressions and predictions of industry professionals to date.
While over three quarters of survey respondents from the pharmaceutical and medical device sectors felt that virtual events would become much more popular in future — rivaling face-to-face events in number — they also highlighted aspects that have been unsatisfactory and need to be re-appraised by event organizers.
Respondents were underwhelmed by many virtual events so far in terms of content, technical platforms, interactivity, price etc., but they remained positive about the potential for creating better experiences in the future. Criticism of virtual events was most vehement where face-to-face methods had simply been put online, with little thought about whether this would work satisfactorily for delegates.
Denis Marteau, General Manager at Owen Mumford Pharmaceutical Services, commented: “There are some areas of the in-person experience which are highly difficult to replace, especially the networking element which is so critical at conferences, and the ability to demonstrate a device and let delegates see how it works. But we see scope for innovative thinking from event organizers and this survey suggests that there is an appetite for this in our industry.”
The report can be accessed here.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.